Krystal Biotech's KB113 Shrinks 83.1% of Assessed Basal Cell Carcinoma Lesions in Gorlin Syndrome Pilot Study

By Public Technologies
  • Krystal Biotech reported regression in 83.1% of assessed basal cell carcinoma lesions with KB113 in a three-patient Gorlin syndrome pilot study.
  • Non-injected lesions showed an 85.1% regression rate, providing preliminary evidence of an abscopal effect.
  • Biopsies confirmed complete tumor clearance in one injected lesion from each patient.
  • All reported adverse events were mild or moderate, transient and resolved during the study.
  • Discussions with the FDA have begun on advanced clinical development of KB113 for Gorlin syndrome.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150700PRIMZONEFULLFEED9846076) on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.